Ink4a/Arf loss promotes tumor recurrence following Ras inhibition

Matthew W. Van Brocklin, James P. Robinson, Kristin J. Lastwika, Andrea J. McKinney, H. Michael Gach, Sheri L. Holmen

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Aberrant activation of rat sarcoma (Ras) signaling contributes to the development of a variety of human cancers, including gliomas. To determine the dependence of high-grade gliomas on continued Ras signaling, we developed a doxycycline-regulated Kirsten Ras (KRas) glioma mouse model. We previously demonstrated that KRas is required for the maintenance of glioblastoma multiforme tumors arising in the context of activated Akt signaling in vivo; inhibition of KRas expression resulted in apoptotic tumor regression and significantly increased survival. We utilized a wellestablished glioma mouse model to determine the reliance of gliomas on continued KRas signaling in the context of Ink4a/Arf deficiency, a common occurrence in human gliomas. Despite the dependency of primary gliomas on continued KRas signaling, a significant percentage of tumors progressed to a KRas-independent state in the absence of Ink4a/Arf expression, demonstrating that these tumor suppressors play a critical role in the suppression of glioma recurrence. While even advanced stages of gliomas may remain dependent upon KRas signaling for maintenance and growth, our findings demonstrate that loss of Ink4a/Arf facilitates the acquisition of oncogene independence and tumor recurrence. Furthermore, reactivation of the Ras mitogen-activated protein kinase pathway in the absence of virally delivered KRas expression is a common mechanism of recurrence in this context.

Original languageEnglish
Pages (from-to)34-42
Number of pages9
JournalNeuro-oncology
Volume14
Issue number1
DOIs
StatePublished - Jan 1 2012
Externally publishedYes

Keywords

  • Glioma
  • Ink4a/Arf
  • Mouse
  • Ras
  • Tumor maintenance

Fingerprint Dive into the research topics of 'Ink4a/Arf loss promotes tumor recurrence following Ras inhibition'. Together they form a unique fingerprint.

  • Cite this

    Van Brocklin, M. W., Robinson, J. P., Lastwika, K. J., McKinney, A. J., Gach, H. M., & Holmen, S. L. (2012). Ink4a/Arf loss promotes tumor recurrence following Ras inhibition. Neuro-oncology, 14(1), 34-42. https://doi.org/10.1093/neuonc/nor184